143 related articles for article (PubMed ID: 32829322)
1. Prolonged Duration of Erythropoiesis-Stimulating Agents' Action Delays Disease Progression in Anti-Thy 1 Antibody-Induced Chronic Glomerulonephritis Rats.
Kawasaki R; Tashiro Y; Yogo K; Serizawa K; Aizawa K; Endo K; Hirata M
Pharmacology; 2021; 106(1-2):45-52. PubMed ID: 32829322
[TBL] [Abstract][Full Text] [Related]
2. Renoprotective effect of epoetin beta pegol by the prevention of M2 macrophage recruitment in Thy-1 rats.
Aizawa K; Tashiro Y; Hirata M; Takeda S; Kawasaki R; Endo K
J Nephrol; 2014 Aug; 27(4):395-401. PubMed ID: 24821659
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients.
Sánchez-Escuredo A; Batista F; Cases A; Torregrosa JV
Transplant Proc; 2015; 47(1):73-5. PubMed ID: 25645774
[TBL] [Abstract][Full Text] [Related]
4. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study.
Kakimoto-Shino M; Toya Y; Kuji T; Fujikawa T; Umemura S
Ther Apher Dial; 2014 Oct; 18(5):421-6. PubMed ID: 24456328
[TBL] [Abstract][Full Text] [Related]
5. A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients.
Toida T; Sato Y; Shibata N; Kitamura K; Fujimoto S
Blood Purif; 2014; 38(3-4):174-9. PubMed ID: 25502179
[TBL] [Abstract][Full Text] [Related]
6. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
Piotr B; Mariusz S; Jacek R
Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
[TBL] [Abstract][Full Text] [Related]
8. Epoetin beta pegol, but not recombinant erythropoietin, retains its hematopoietic effect in vivo in the presence of the sialic acid-metabolizing enzyme sialidase.
Aizawa K; Kawasaki R; Tashiro Y; Hirata M; Endo K; Shimonaka Y
Int J Hematol; 2016 Aug; 104(2):182-9. PubMed ID: 27084258
[TBL] [Abstract][Full Text] [Related]
9. Pleiotropic effect of erythropoiesis-stimulating agents on circulating endothelial progenitor cells in dialysis patients.
Naito T; Shun M; Nishimura H; Gibo T; Tosaka M; Kawashima M; Ando A; Ogawa T; Sanaka T; Nitta K
Clin Exp Nephrol; 2021 Oct; 25(10):1111-1120. PubMed ID: 34106373
[TBL] [Abstract][Full Text] [Related]
10. Antibody-mediated pure red cell aplasia related with epoetin-beta pegol (C.E.R.A.) as an erythropoietic agent: case report of a dialysis patient.
Shingu Y; Nakata T; Sawai S; Tanaka H; Asai O; Tamagaki K; Nakatani K
BMC Nephrol; 2020 Jul; 21(1):275. PubMed ID: 32664894
[TBL] [Abstract][Full Text] [Related]
11. C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
Bastos K; Lucarelli LA; De Francesco-Daher E; Filho RP; Henríquez C; Espinoza B; Villanueva I; Schwedt E; Schiavelli R; Correa-Rotter R
Int Urol Nephrol; 2013 Oct; 45(5):1355-64. PubMed ID: 22990412
[TBL] [Abstract][Full Text] [Related]
12. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.
Forbes CA; Worthy G; Harker J; Kleijnen J; Kutikova L; Zelek L; Van Belle S
Clin Ther; 2014 Apr; 36(4):594-610. PubMed ID: 24656152
[TBL] [Abstract][Full Text] [Related]
13. Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials.
Locatelli F; Choukroun G; Truman M; Wiggenhauser A; Fliser D
Adv Ther; 2016 Apr; 33(4):610-25. PubMed ID: 26965694
[TBL] [Abstract][Full Text] [Related]
14. Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin.
Tsuruya K; Yoshida H; Suehiro T; Fujisaki K; Masutani K; Kitazono T
Ren Fail; 2016; 38(3):390-6. PubMed ID: 26822074
[TBL] [Abstract][Full Text] [Related]
15. Epoetin beta pegol prevents endothelial dysfunction as evaluated by flow-mediated dilation in chronic kidney disease rats.
Serizawa K; Yogo K; Tashiro Y; Aizawa K; Kawasaki R; Hirata M; Endo K
Eur J Pharmacol; 2015 Nov; 767():10-6. PubMed ID: 26432688
[TBL] [Abstract][Full Text] [Related]
16. Time savings associated with C.E.R.A. once monthly: a time-and-motion study in hemodialysis centers in five European countries.
De Cock E; Dellanna F; Khellaf K; Klatko W; Maduell F; Raluy-Callado M; Villa G
J Med Econ; 2013; 16(5):648-56. PubMed ID: 23402559
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin mimetic peptides and erythropoietin fusion proteins for treating anemia of chronic kidney disease.
Gupta N; Wish JB
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):345-350. PubMed ID: 29746307
[TBL] [Abstract][Full Text] [Related]
18. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
Nurko S; Spirko R; Law A; Dennis VW
Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 2-week versus 4-week dosing intervals of epoetin beta pegol on erythropoiesis and iron metabolism in hemodialysis patients.
Morikami Y; Fujimori A; Okada S; Kumei M; Mizobuchi N; Sakai M
Ther Apher Dial; 2014 Oct; 18(5):414-20. PubMed ID: 24456373
[TBL] [Abstract][Full Text] [Related]
20. Epoetin beta pegol (C.E.R.A.) promotes utilization of iron for erythropoiesis through intensive suppression of serum hepcidin levels in mice.
Sasaki Y; Noguchi-Sasaki M; Matsuo-Tezuka Y; Matsumoto-Omori Y; Kurasawa M; Yorozu K; Shimonaka Y
Int J Hematol; 2014; 99(5):561-9. PubMed ID: 24623262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]